How does tazemetostat actually fight cancer inside my body?
Tazemetostat blocks an enzyme called EZH2 that cancer cells use to hide from your immune system. By shutting down EZH2, the medicine lets your body recognize and kill lymphoma and sarcoma cells. Clinical trials show 60–71% of patients see their tumors shrink [1][2].
In phase 2 trials, 60% of patients with relapsed/refractory follicular lymphoma had their tumors shrink by at least 30%, and 35% saw complete disappearance [1]. Epithelioid sarcoma patients (a rare soft-tissue cancer) showed even higher response rates—71%—with responses lasting over 2 years in some cases [2]. These numbers come straight from FDA-approved clinical data, not marketing claims.
Inside your cells, EZH2 is a protein that cancer uses like a cloak to stay invisible. Tazemetostat rips off that cloak by blocking the enzyme's ability to add chemical tags to DNA. Once the cloak is gone, your T cells and natural killer cells spot the cancer and attack it—the same way your immune system fights a cold [6].
The trade-off is that blocking EZH2 also affects healthy blood cells, which is why anemia (low red blood cells) and infection risk are the most common side effects [1]. Your oncologist will check your blood counts every 2–4 weeks to catch problems early. If your counts drop too far, your doctor may pause the medicine briefly or reduce the dose [9].
Ask your oncologist: 'How often will you check my blood counts, and what number triggers a dose pause?' This one question ensures you stay safe and avoid surprise hospitalizations for low blood counts.